I personally think that part of the reductions are coming from foreign healthcare screenings (off the books) and/or a combination of early term options).
The cost for treatment [1] may have some considering alternate options for screenings and treatment after seeing someone elses experience/ordeal beforehand or reading about first-hand accounts online.
The reductions are absolutely coming from new treatments in particular immunotherapy.
When I started Med school 19 years ago the average survival of metastatic melanoma was 6 months, it is now closer to 5 years (ie basically remission). Many other cancers (including lung, which this article pinpoints as being the main driver in falls over the last 12 months) are now benefiting from the second and third generation of these drugs
The cost for treatment [1] may have some considering alternate options for screenings and treatment after seeing someone elses experience/ordeal beforehand or reading about first-hand accounts online.
[1] https://www.aarp.org/money/credit-loans-debt/info-2018/the-h...